z-logo
open-access-imgOpen Access
New Therapeutic Avenues of mCSF for Brain Diseases and Injuries
Author(s) -
Vincent Pons,
Serge Rivest
Publication year - 2018
Publication title -
frontiers in cellular neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.877
H-Index - 86
ISSN - 1662-5102
DOI - 10.3389/fncel.2018.00499
Subject(s) - microglia , chemokine , inflammation , microbiology and biotechnology , immune system , proinflammatory cytokine , macrophage colony stimulating factor , ccl2 , macrophage , neuroscience , myelin , immunology , biology , chemistry , central nervous system , in vitro , biochemistry
Macrophage colony-stimulating factor (mCSF) is a cytokine known to promote the recruitment of macrophages inducing the release of CCL2, a chemokine mobilizing monocytes to sites of inflammation. Additionally, it induces microglia/macrophage proliferation and the polarization of these cells towards a M2-like phenotype, impairing their ability to release pro-inflammatory factors and toxic mediators, while favoring the release of mediators promoting tissue repair. Another important player is the mCSF receptor CSFR1, which is highly expressed in monocytes, macrophages and microglia. Here, we discuss the new interesting therapeutic avenue of the mCSF/CSFR1 axis on brain diseases. More specifically, mCSF cascade might stimulate the survival/proliferation of oligodendrocytes, enhance the immune response as well as modulate the release of growth factors and the phagocytic activity of immune cells to remove myelin debris and toxic proteins from the brain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom